Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Nuclear Area is a Prognostic Determinant in Advanced Colorectal Cancer

ABDELBASET BUHMEIDA, RAIJA RISTAMÄKI, HANAN LAMLUM, RIYAD BENDARDAF, SUVI HEIKKILÄ, YRJÖ COLLAN, KARI SYRJÄNEN and SEPPO PYRHÖNEN
Anticancer Research July 2005, 25 (4) 3083-3088;
ABDELBASET BUHMEIDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: abuhme@utu.fi
RAIJA RISTAMÄKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANAN LAMLUM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RIYAD BENDARDAF
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUVI HEIKKILÄ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YRJÖ COLLAN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KARI SYRJÄNEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEPPO PYRHÖNEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The prognostic value of morphometric nuclear features in Dukes' Stages B/C and D colorectal cancer (CRC) was assessed. Patients and Methods: Primary tumours from 86 CRC patients were analysed, using an image overlay drawing system (Prodit Morphometry Program), for the following nuclear features: area, perimeter, diameter, form factor, roundness. Results: The median nuclear area (NA) was 104.6 μm2 (range 57.2 - 237.2 μm2). The NA was larger in patients with lymph node metastasis (p<0.02). Altogether, 43% of the patients showed clinical response to irinotecan-based chemotherapy. All six patients with complete response (CR) had a NA above the median (p<0.03). The disease-specific survival of the patients with a NA above the median was significantly better than in patients with smaller NA (p<0.02). Conclusion: Using the median NA as the cut-off value seems to effectively discriminate patients who are likely to respond to irinotecan-based chemotherapy (with improved prognosis) from those who are non-responsive and develop progressive disease.

  • Nuclear morphometry
  • nuclear area
  • colorectal cancer
  • prognosis
  • adjuvant therapy

Footnotes

  • Received February 21, 2005.
  • Accepted May 17, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nuclear Area is a Prognostic Determinant in Advanced Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Nuclear Area is a Prognostic Determinant in Advanced Colorectal Cancer
ABDELBASET BUHMEIDA, RAIJA RISTAMÄKI, HANAN LAMLUM, RIYAD BENDARDAF, SUVI HEIKKILÄ, YRJÖ COLLAN, KARI SYRJÄNEN, SEPPO PYRHÖNEN
Anticancer Research Jul 2005, 25 (4) 3083-3088;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Nuclear Area is a Prognostic Determinant in Advanced Colorectal Cancer
ABDELBASET BUHMEIDA, RAIJA RISTAMÄKI, HANAN LAMLUM, RIYAD BENDARDAF, SUVI HEIKKILÄ, YRJÖ COLLAN, KARI SYRJÄNEN, SEPPO PYRHÖNEN
Anticancer Research Jul 2005, 25 (4) 3083-3088;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study
  • Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI)
  • Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire